CN109475592B - 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物 - Google Patents

用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物 Download PDF

Info

Publication number
CN109475592B
CN109475592B CN201780043923.7A CN201780043923A CN109475592B CN 109475592 B CN109475592 B CN 109475592B CN 201780043923 A CN201780043923 A CN 201780043923A CN 109475592 B CN109475592 B CN 109475592B
Authority
CN
China
Prior art keywords
residue
ethoxy
amino
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780043923.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109475592A (zh
Inventor
J.阿尔西纳-费尔南德斯
郭莉莉
J.李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN109475592A publication Critical patent/CN109475592A/zh
Application granted granted Critical
Publication of CN109475592B publication Critical patent/CN109475592B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
CN201780043923.7A 2016-07-15 2017-07-13 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物 Active CN109475592B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662362711P 2016-07-15 2016-07-15
US62/362711 2016-07-15
US201662431682P 2016-12-08 2016-12-08
US62/431682 2016-12-08
US201762491385P 2017-04-28 2017-04-28
US62/491385 2017-04-28
PCT/US2017/041922 WO2018013803A1 (en) 2016-07-15 2017-07-13 Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

Publications (2)

Publication Number Publication Date
CN109475592A CN109475592A (zh) 2019-03-15
CN109475592B true CN109475592B (zh) 2022-08-09

Family

ID=59501524

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780043923.7A Active CN109475592B (zh) 2016-07-15 2017-07-13 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物

Country Status (24)

Country Link
US (1) US10894817B2 (ja)
EP (1) EP3484495B1 (ja)
JP (1) JP2019525919A (ja)
KR (1) KR20190017982A (ja)
CN (1) CN109475592B (ja)
AU (1) AU2017295708B2 (ja)
BR (1) BR112018076693A2 (ja)
CA (1) CA3030965C (ja)
CL (1) CL2019000043A1 (ja)
CO (1) CO2018014026A2 (ja)
CR (1) CR20190015A (ja)
DO (1) DOP2019000007A (ja)
EC (1) ECSP19003047A (ja)
ES (1) ES2901477T3 (ja)
IL (1) IL264025A (ja)
JO (1) JOP20170153A1 (ja)
MA (1) MA45673A (ja)
MX (1) MX2019000661A (ja)
PE (1) PE20190470A1 (ja)
PH (1) PH12019500074A1 (ja)
SG (1) SG11201811737SA (ja)
SV (1) SV2019005808A (ja)
TW (1) TW201811821A (ja)
WO (1) WO2018013803A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
SI3436461T1 (sl) 2016-03-28 2024-03-29 Incyte Corporation Pirolotriazinske spojine kot tam-inhibitorji
PE20210002A1 (es) 2017-09-27 2021-01-05 Incyte Corp Sales de derivados de pirrolotriazina utiles como inhibidores tam
WO2019140021A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140024A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140023A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140025A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3813800A1 (en) 2018-06-29 2021-05-05 Incyte Corporation Formulations of an axl/mer inhibitor
US20200027555A1 (en) * 2018-07-17 2020-01-23 Lewis Pharmaceutical Information, Inc. Patient centric drug analysis platform
JP2023541798A (ja) 2020-08-19 2023-10-04 サノフイ Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
JP2023554693A (ja) 2021-01-20 2023-12-28 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023285347A1 (en) * 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
EP4234574A1 (en) 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000063A2 (en) * 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
WO2002012307A1 (en) * 2000-08-04 2002-02-14 Research Development Foundation Urocortin proteins and uses thereof
WO2003062268A2 (en) * 2002-01-16 2003-07-31 The Procter & Gamble Company Corticotropin releasing factor receptor 2 agonists
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2011025905A1 (en) * 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE171212T1 (de) 1994-06-14 1998-10-15 Neurocrine Biosciences Inc Corticotropin freisetzende rezeptoren des faktor 2
US20040034882A1 (en) 1999-07-15 2004-02-19 Vale Wylie W. Corticotropin releasing factor receptor 2 deficient mice and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
AU2002306853B2 (en) 2001-03-15 2006-07-06 Research Development Foundation Urocortin-III and uses thereof
GR1004664B (en) 2002-11-26 2004-09-02 Bionature E A Ltd The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references
WO2005103690A2 (en) 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
CA2576435A1 (en) 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis
CA2597065C (en) 2005-02-08 2014-10-14 Research Development Foundation Compositions and methods related to soluble g-protein coupled receptors (sgpcrs)
WO2007090087A2 (en) 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
EP2167094A2 (en) 2007-06-13 2010-03-31 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
CA2742710A1 (en) * 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
MX2012005262A (es) 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
MX2016012558A (es) 2014-04-03 2017-01-09 Univ California Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo.
AR104932A1 (es) * 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000063A2 (en) * 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
WO2002012307A1 (en) * 2000-08-04 2002-02-14 Research Development Foundation Urocortin proteins and uses thereof
WO2003062268A2 (en) * 2002-01-16 2003-07-31 The Procter & Gamble Company Corticotropin releasing factor receptor 2 agonists
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2011025905A1 (en) * 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Interplay between Chaperones and Protein Disorder Promotes the Evolution of Protein Networks;Sebastian Pechmann等;《PLoS Comput Biol》;20140626;第10卷(第6期);e1003674 *
Modifications of the human urocortin 2 peptide that improve pharmacological properties;Robert J.Isfort等;《Peptides》;20060701;第27卷(第7期);第1806-1813页 *
N-terminal modifications of cellular proteins: The enzymes involved, their substrate specificities and biological effects;Sylvia Varland等;《Proteomics》;20150731;第15卷(第14期);第2385-2401页 *

Also Published As

Publication number Publication date
CR20190015A (es) 2019-02-27
US10894817B2 (en) 2021-01-19
JP2019525919A (ja) 2019-09-12
ECSP19003047A (es) 2019-01-31
SG11201811737SA (en) 2019-01-30
IL264025A (en) 2019-01-31
EP3484495B1 (en) 2021-09-08
BR112018076693A2 (pt) 2019-04-02
AU2017295708A1 (en) 2018-12-20
CA3030965A1 (en) 2018-01-18
MX2019000661A (es) 2019-05-15
JOP20170153A1 (ar) 2019-01-30
MA45673A (fr) 2021-05-26
PH12019500074A1 (en) 2019-07-29
AU2017295708B2 (en) 2019-05-09
CN109475592A (zh) 2019-03-15
CO2018014026A2 (es) 2019-01-18
SV2019005808A (es) 2019-04-04
PE20190470A1 (es) 2019-04-04
WO2018013803A1 (en) 2018-01-18
CA3030965C (en) 2022-04-26
US20180016318A1 (en) 2018-01-18
TW201811821A (zh) 2018-04-01
CL2019000043A1 (es) 2019-06-07
EP3484495A1 (en) 2019-05-22
KR20190017982A (ko) 2019-02-20
ES2901477T3 (es) 2022-03-22
DOP2019000007A (es) 2019-04-15

Similar Documents

Publication Publication Date Title
CN109475592B (zh) 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物
CN107735100B (zh) 胰高血糖素和glp-1协同激动剂化合物
US11382956B2 (en) Amylin analogues
TWI642682B (zh) 升糖素類似物
AU2003200839B2 (en) Extended glucagon-like peptide-1 analogs
TWI781118B (zh) 作為神經肽ｙ受體調節劑之環狀酪酪肽化合物
JP4148994B2 (ja) グルカゴン様ペプチド―２アナログ
JP2021185178A (ja) 胆汁酸に関係した障害の治療方法
CA2236519C (en) Methods of enhancing functioning of the large intestine
TW202138385A (zh) 腸促胰島素(incretin)類似物及其用途
CA3197916A1 (en) Compounds and their use in treatment of tachykinin receptor mediated disorders
TW202241933A (zh) 多肽及其用途
WO2019140030A1 (en) Combination therapy
WO2019140025A1 (en) Combination therapy
CN117603337A (zh) 酰化胃泌酸调节素肽类似物
Niida et al. Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives
EP3842061A1 (en) Stapled triazole co-agonists of the glucagon and glp-1 receptors
WO2023207106A1 (zh) Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
WO2019140021A1 (en) Combination therapy
WO2019140024A1 (en) Combination therapy
WO2019140023A1 (en) Combination therapy
CN115960258A (zh) 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
US20240270821A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
KR20100033480A (ko) 혈압 강하 활성을 가지는 펩티드

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005282

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant